Mitochon Pharmaceuticals: Pioneering Brain Injury Solutions through Mitochondrial Innovation
September 23, 2024
Brain injuries present significant challenges globally, affecting countless lives in our modern world. Whether resulting from sudden accidents or ongoing neurological issues, these injuries go beyond mere physical harm, often reshaping individuals’ entire existence. Within this challenging environment, the need for better treatment options has been more urgent than ever. However, traditional approaches often fall short, leaving many without hope for meaningful recovery.
About Mitochon Pharmaceuticals
Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and developmental diseases. Mitochon’s lead programs, MP101 and MP201, specifically harnesses the power of the mitochondria to provide broad neural protection. These compounds elicit mild increases in energy expenditure that result in strengthening cellular survival—similar to the positive effects seen with fasting and exercise. These compounds also induce an important neurotrophin, Brain Derived Neurotrophic Factor (BDNF), involved in cognition and neural growth. Mitochon is supported by Ben Franklin Technology Partners Southeastern PA, an initiative of the Pennsylvania Department of Community and Economic Development funded by the Ben Franklin Technology Development Authority.